| Literature DB >> 32212084 |
Yu-Chuan Yen1, Chun-Yuh Yang1, Tsu-Nai Wang1, Pei-Chun Yen1, Chi-Kung Ho1, Kristina D Mena2, Tzu-Chi Lee1,3, Kang-Shin Chen4, Yuan-Chung Lin4, Pei-Shih Chen5,6,7,8.
Abstract
To evaluate the association between the presence of asthma and allergy, and airborne endotoxin in homes of school-age children in Kaohsiung City, Taiwan, with a case-control study design by matching the age and class exposure. Data collection of home visits included an interviewer-administered questionnaire and air sampling of participants' homes for endotoxin, bacteria, and fungi, as well as temperature and relative humidity measurements. Endotoxin was detected in all air samples with a median value of 0.67 EU m-3. In the adjusted logistic regression model, household airborne endotoxin was associated with higher prevalence of asthma and allergy; OR = 4.88 (95% CI 1.16-20.55) for Q3 (between 0.67 and 1.97 EU m -3) vs. Q1 (< 0.31 EU m -3), with statistical significance. Airborne fungi were associated with higher prevalence of asthma and allergy; OR = 4.47 (95% CI 1.13-17.69) for Q3 (between 314 and 699 CFU m -3) vs. Q1 (< 159 CFU m -3) in adjusted logistic regression models. Airborne endotoxin and fungi were significantly associated with children's asthma and allergy.Entities:
Keywords: Airborne endotoxin; Allergy; Asthma; Bacterial bioaerosol; Children; Fungal bioaerosols
Mesh:
Substances:
Year: 2020 PMID: 32212084 PMCID: PMC7244453 DOI: 10.1007/s11356-020-07899-x
Source DB: PubMed Journal: Environ Sci Pollut Res Int ISSN: 0944-1344 Impact factor: 4.223
Descriptive statistics of airborne endotoxin, bacteria, and fungi concentration, temperature, and relative humidity
| Mean | Standard deviation | 25th percentile | Median (50th percentile) | 75th percentile | Minimum | Maximum | |
|---|---|---|---|---|---|---|---|
| Airborne endotoxin (EU m−3) | 1.40 | 0.16 | 0.31 | 0.67 | 1.97 | 0.02 | 8.13 |
| Airborne bacteria (CFU m−3) | 1771 | 156 | 557 | 1411 | 2468 | 129 | 7008 |
| Airborne fungi (CFU m−3) | 548 | 61 | 159 | 314 | 699 | 44 | 4014 |
| Temperature (°C) | 30.63 | 0.20 | 29.51 | 31.13 | 31.89 | 23.30 | 34.33 |
| Relative humidity (%) | 72.26 | 0.47 | 69.22 | 72.09 | 75.84 | 60.48 | 83.67 |
Odds ratios (ORs) for association of airborne endotoxin with respiratory disease and symptoms
| Airborne endotoxin exposurea | Crude OR (95% CIb) | Adjusted OR(95% CIb) | |||
|---|---|---|---|---|---|
| Have been diagnosed | |||||
| Asthma and allergy | Q2 vs. Q1 | 0.49 (0.18–1.35) | 0.17 | 0.73 (0.15–3.49) | 0.70 |
| Q3 vs. Q1 | 2.05 (0.73–5.74) | 0.17 | 4.88 (1.16–20.55)* | 0.03 | |
| Q4 vs. Q1 | 0.51 (0.19–1.37) | 0.18 | 0.70 (0.16–3.06) | 0.64 | |
| Sinusitis | Q2 vs. Q1 | 0.71 (0.16–3.11) | 0.65 | 0.99 (0.19–5.17) | 0.99 |
| Q3 vs. Q1 | 0.46 (0.13–1.64) | 0.23 | 0.57 (0.14–2.37) | 0.44 | |
| Q4 vs. Q1 | 1.14 (0.24–5.42) | 0.87 | 1.30 (0.25–6.86) | 0.76 | |
| Wheeze | Q2 vs. Q1 | 1.09 (0.23–5.16) | 0.91 | 1.14 (0.20–6.36) | 0.88 |
| Q3 vs. Q1 | 0.76 (0.20–2.98) | 0.70 | 0.57 (0.12–2.58) | 0.46 | |
| Q4 vs. Q1 | 0.82 (0.19–3.48) | 0.79 | 0.66 (0.14–3.07) | 0.59 | |
| Allergic rhinitis | Q2 vs. Q1 | 0.37 (0.09–1.53) | 0.17 | 0.25 (0.05–1.26) | 0.09 |
| Q3 vs. Q1 | 0.37 (0.11–1.26) | 0.11 | 0.30 (0.07–1.25) | 0.10 | |
| Q4 vs. Q1 | 0.92 (0.22–3.92) | 0.91 | 0.81 (0.17–3.82) | 0.79 | |
| Allergic eczema | Q2 vs. Q1 | 0.47 (0.08–2.83) | 0.41 | 0.44 (0.06–3.33) | 0.42 |
| Q3 vs. Q1 | 3.00 (0.29–31.48) | 0.36 | 2.21 (0.17–29.64) | 0.55 | |
| Q4 vs. Q1 | 0.58 (0.10–3.38) | 0.54 | 0.55 (0.06–5.36) | 0.61 | |
| Bronchitis | Q2 vs. Q1 | 1.23 (0.35–4.34) | 0.75 | 1.54 (0.38–6.22) | 0.54 |
| Q3 vs. Q1 | 1.26 (0.42–3.77) | 0.68 | 1.34 (0.39–4.57) | 0.64 | |
| Q4 vs. Q1 | 1.48 (0.45–4.90) | 0.52 | 1.92 (0.52–7.16) | 0.33 | |
| Pneumonia | Q2 vs. Q1 | 1.31 (0.22–7.88) | 0.77 | 5.55 (0.44–69.89) | 0.19 |
| Q3 vs. Q1 | 1.43 (0.30–6.82) | 0.65 | 0.90 (0.14–5.92) | 0.91 | |
| Q4 vs. Q1 | 1.03 (0.21–5.06) | 0.97 | 1.29 (0.20–8.38) | 0.79 | |
| In the past 12 months | |||||
| Sinusitis | Q2 vs. Q1 | 0.28 (0.05–1.53) | 0.14 | 0.34 (0.03–3.59) | 0.37 |
| Q3 vs. Q1 | 0.36 (0.08–1.69) | 0.19 | 0.27 (0.04–1.79) | 0.18 | |
| Q4 vs. Q1 | 2.22 (0.22–22.70) | 0.50 | 5.77 (0.23–143.42) | 0.28 | |
| Wheeze | Q2 vs. Q1 | 0.16 (0.02–1.28) | 0.08 | 2.86 (0.03–311.76) | 0.66 |
| Q3 vs. Q1 | 0.30 (0.04–2.27) | 0.24 | 0.21 (0.02–2.51) | 0.22 | |
| Q4 vs. Q1 | 0.51 (0.068–4.43) | 0.54 | 1.18 (0.08–17.99) | 0.90 | |
aQ1, 1st quartile < 0.31 EU m−3; Q2, 2nd quartile 0.31–0.67 EU m−3; Q3, 3rd quartile 0.67–1.97 EU m−3; Q4, 4th quartile > 1.97 EU m−3
b95% confidence intervals
Odds ratios (ORs) for association of airborne bacteria with respiratory disease and symptoms
| Airborne bacteria exposurea | Crude OR (95% CIb) | Adjusted OR (95% CIb) | |||
|---|---|---|---|---|---|
| Have been diagnosed | |||||
| Asthma and allergy | Q2 vs. Q1 | 0.99 (0.37–2.62) | 0.98 | 1.58 (0.44–5.70) | 0.49 |
| Q3 vs. Q1 | 1.46 (0.54–3.94) | 0.46 | 0.72 (0.18–2.81) | 0.63 | |
| Q4 vs. Q1 | 1.34 (0.51–3.56) | 0.56 | 1.15 (0.28–4.65) | 0.85 | |
| Sinusitis | Q2 vs. Q1 | 1.58 (0.40–6.15) | 0.51 | 1.78 (0.36–8.69) | 0.48 |
| Q3 vs. Q1 | 0.99 (0.27–3.70) | 0.99 | 1.89 (0.38–9.36) | 0.43 | |
| Q4 vs. Q1 | 1.65 (0.37–7.39) | 0.51 | 2.07 (0.38–11.25) | 0.40 | |
| Wheeze | Q2 vs. Q1 | 0.67 (0.16–2.92) | 0.60 | 0.59 (0.12–3.02) | 0.52 |
| Q3 vs. Q1 | 0.26 (0.06–1.07) | 0.06 | 0.25 (0.05–1.18) | 0.08 | |
| Q4 vs. Q1 | 0.77 (0.16–3.76) | 0.75 | 0.59 (0.11–3.19) | 0.54 | |
| Allergic rhinitis | Q2 vs. Q1 | 1.77 (0.45–6.98) | 0.42 | 1.76 (0.39–7.89) | 0.46 |
| Q3 vs. Q1 | 0.52 (0.14–1.85) | 0.31 | 0.65 (0.17–2.52) | 0.53 | |
| Q4 vs. Q1 | 1.06 (0.28–4.06) | 0.93 | 0.98 (0.23–4.18) | 0.98 | |
| Allergic eczema | Q2 vs. Q1 | 0.38 (0.06–2.56) | 0.32 | 0.57 (0.05–6.63) | 0.65 |
| Q3 vs. Q1 | 0.16 (0.03–0.96)* | 0.04 | 0.10 (001–1.0)* | 0.05 | |
| Q4 vs. Q1 | – | 0.95 | – | 0.97 | |
| Bronchitis | Q2 vs. Q1 | 1.49 (0.45–4.89) | 0.52 | 1.48 (0.39–5.57) | 0.57 |
| Q3 vs. Q1 | 0.87 (0.25–2.96) | 0.82 | 0.76 (0.20–2.89) | 0.69 | |
| Q4 vs. Q1 | 1.44 (0.41–5.07) | 0.57 | 1.33 (0.33–5.37) | 0.69 | |
| Pneumonia | Q2 vs. Q1 | 1.14 (0.24–5.49) | 0.87 | 1.77 (0.30–10.39) | 0.53 |
| Q3 vs. Q1 | 0.99 (0.20–4.82) | 0.99 | 2.35 (0.30–18.34) | 0.42 | |
| Q4 vs. Q1 | 1.48 (0.25–8.73) | 0.67 | 1.13 (0.16–7.86) | 0.90 | |
| In the past 12 months | |||||
| Sinusitis | Q2 vs. Q1 | – | 0.96 | – | 0.96 |
| Q3 vs. Q1 | 1.40 (0.29–6.83) | 0.68 | 0.51 (0.05–5.91) | 0.59 | |
| Q4 vs. Q1 | 0.47 (0.09–2.43) | 0.37 | 0.13 (0.01–1.55) | 0.11 | |
| Wheeze | Q2 vs. Q1 | 3.75 (0.33–43.28) | 0.29 | 3.09 (0.15–63.44) | 0.46 |
| Q3 vs. Q1 | 0.56 (0.09–3.52) | 0.54 | 0.81 (0.09–6.99) | 0.85 | |
| Q4 vs. Q1 | 2.63 (0.22–31.35) | 0.45 | 2.46 (0.17–35.21) | 0.51 | |
aQ1, 1st quartile < 577 CFU m−3; Q2, 2nd quartile 557–1411 CFU m−3; Q3, 3rd quartile 1411–2468 CFU m−3; Q4, 4th quartile > 24,687 CFU m−3
b95% confidence interval
Odds ratios (ORs) for association of airborne fungi with respiratory disease and symptoms
| Airborne fungi exposurea | Crude OR (95% CIb) | Adjusted OR (95% CIb) | |||
|---|---|---|---|---|---|
| Have been diagnosed | |||||
| Asthma and allergy | Q2 vs. Q1 | 1.87 (0.69–5.03) | 0.22 | 1.86 (0.43–7.93) | 0.40 |
| Q3 vs. Q1 | 3.53 (1.27–9.80)* | 0.02 | 4.47 (1.13–17.69)* | 0.03 | |
| Q4 vs. Q1 | 2.80 (1.01–7.74)* | 0.05 | 2.91 (0.75–11.27) | 0.12 | |
| Sinusitis | Q2 vs. Q1 | 1.54 (0.39–6.08) | 0.54 | 1.53 (0.27–8.57) | 0.63 |
| Q3 vs. Q1 | 1.04 (0.28–3.91) | 0.95 | 1.47 (0.31–6.87) | 0.63 | |
| Q4 vs. Q1 | 2.05 (0.47–9.06) | 0.34 | 2.08 (0.41–10.69) | 0.38 | |
| Wheeze | Q2 vs. Q1 | 0.48 (0.13–1.70) | 0.26 | 0.44 (0.10–2.02) | 0.29 |
| Q3 vs. Q1 | 3.96 (0.44–35.81) | 0.22 | 4.84 (0.51–45.64) | 0.17 | |
| Q4 vs. Q1 | 1.32 (0.29–5.99) | 0.72 | 1.54 (0.30–7.85) | 0.60 | |
| Allergic rhinitis | Q2 vs. Q1 | 1.10 (0.28–4.27) | 0.89 | 0.89 (0.18–4.45) | 0.89 |
| Q3 vs. Q1 | 1.15(0.32–4.08) | 0.83 | 1.19 (0.30–4.71) | 0.81 | |
| Q4 vs. Q1 | 1.51 (0.41–5.59) | 0.53 | 1.96 (0.47–8.29) | 0.36 | |
| Allergic eczema | Q2 vs. Q1 | 0.43 (0.09–2.10) | 0.30 | 0.77 (0.07–7.92) | 0.82 |
| Q3 vs. Q1 | 2.86 (0.29–28.17) | 0.37 | 3.19 (0.27–37.40) | 0.36 | |
| Q4 vs. Q1 | 2.48 (0.25–24.64) | 0.44 | 4.08 (0.28–60.54) | 0.31 | |
| Bronchitis | Q2 vs. Q1 | 1.83 (0.53–6.34) | 0.34 | 1.56 (0.37–6.57) | 0.54 |
| Q3 vs. Q1 | 1.00 (0.31–3.27) | 1.00 | 0.90 (0.24–3.39) | 0.88 | |
| Q4 vs. Q1 | 2.20 (0.61–8.00) | 0.23 | 2.07 (0.53–8.15) | 0.30 | |
| Pneumonia | Q2 vs. Q1 | 0.99 (0.20–4.82) | 0.99 | 1.03 (0.15–7.26) | 0.98 |
| Q3 vs. Q1 | 0.74 (0.17–3.25) | 0.69 | 0.87 (0.15–4.96) | 0.88 | |
| Q4 vs. Q1 | 3.41 (0.36–32.19) | 0.28 | 3.34 (0.30–36.86) | 0.32 | |
| In the past 12 months | |||||
| Sinusitis | Q2 vs. Q1 | 1.46 (0.31–6.98) | 0.64 | 3.18 (0.16–63.94) | 0.45 |
| Q3 vs. Q1 | 1.02 (0.20–5.15) | 0.98 | 0.10 (0.004–2.96) | 0.18 | |
| Q4 vs. Q1 | 3.50 (0.37–33.55) | 0.28 | – | 0.05 | |
| Wheeze | Q2 vs. Q1 | 1.09 (0.15–7.80) | 0.93 | 1.73 (0.15–19.93) | 0.66 |
| Q3 vs. Q1 | 1.27 (0.18–8.89) | 0.81 | 4.60 (0.23–93.01) | 0.32 | |
| Q4 vs. Q1 | 2.55 (0.23–27.71) | 0.44 | 11.58 (0.44–305.03) | 0.14 | |
aQ1, 1st quartile < 159 CFU m−3; Q2, 2nd quartile 159–314 CFU m−3; Q3, 3rd quartile 314–699 CFU m−3; Q4, 4th quartile > 699 CFU m−3
b95% confidence interval